Managers / Q3 2022 · view latest →
EPIQ PARTNERS, LLC
CIK 0001799435 · 2919 KNOX AVENUE S, STE 200, MINNEAPOLIS, MN, 55408 · 6128434803
Summary
Epiq Partners, LLC reported $162M in U.S.-listed holdings across 80 positions for Q3 2022.
Its largest position, HRL, represents 11.5% of the portfolio.
Compared with Q2 2022, the fund opened 2 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 57.5% · $93M
- ETP · 16.0% · $26M
- Other · 9.2% · $15M
- US DOMESTIC · 8.4% · $14M
- Closed-End Fund · 4.6% · $7M
- Other · 4.3% · $7M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2022 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| NOVAVAX INC | NEW | +2.30M | 2.30M | +$2M | $2M |
| PGPROCTER AND GAMBLE CO | NEW | +1.7K | 1.7K | +$212,000 | $212,000 |
| GOOGALPHABET INC | ADDED | +3.2K | 3.3K | −$5,000 | $319,000 |
| GOOGLALPHABET INC | ADDED | +36.9K | 38.7K | −$363,000 | $4M |
| TSLATESLA INC | ADDED | +968 | 1.4K | +$60,000 | $384,000 |
| MIC2USDMACQUARIE INFRASTR HOLD LLC | SOLD OUT | −894.8K | 0 | −$3M | $0 |
| VTGNUSDVISTAGEN THERAPEUTICS INC | SOLD OUT | −1.30M | 0 | −$1M | $0 |
| ISHARES TR | SOLD OUT | −2.7K | 0 | −$215,000 | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2022
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q2 2026 | $236M | 99 | Jul 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q1 2026 | $214M | 83 | Apr 9, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $214M | 75 | Jan 7, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $212M | 74 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $196M | 72 | Jul 9, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $190M | 75 | Apr 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $185M | 74 | Jan 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $181M | 79 | Oct 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $148M | 73 | Jul 10, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $150M | 75 | Apr 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $139M | 69 | Jan 11, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $132M | 67 | Oct 18, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $147M | 77 | Jul 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $145M | 77 | Apr 12, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $150M | 75 | Jan 6, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $162M | 80 | Oct 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $163M | 83 | Jul 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $186M | 90 | Apr 27, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $188M | 88 | Jan 25, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $217M | 95 | Oct 19, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $200M | 91 | Aug 2, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $175M | 84 | Apr 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $144M | 77 | Jan 11, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $133M | 75 | Oct 22, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $110M | 61 | Aug 3, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $90M | 63 | Apr 20, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $98M | 64 | Feb 7, 2020 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.